SAVE MONEY ON TRAVEL DEALS

Researchers at the University of Pennsylvania School of Medicine and colleagues at Sangamo BioSciences Inc. of Richmond, Calif., said their goal is to use modified T cells from an HIV-infected person for that person's own treatment. They showed that, by using the zinc fingers, they could reduce the viral load of immune-deficient mice transplanted with engineered T cells.

The researchers, led by Dr. Elena Perez, an assistant professor of pediatrics, and Dr. Carl June, a professor of pathology and laboratory medicine at Penn, are planning a clinical trial in humans in which T cells from HIV patients would have their CCR5 gene -- necessary for the AIDS virus to enter immune system cells -- deliberately knocked out.

The modified T cells could then be infused back into the patients to re-establish their immune system and decrease their viral load.

The research is reported online in the journal Nature Biotechnology.

 BREAKING STORIES

Nobel Prize in medicine awarded to three

CDC: More than 1 million have HIV in U.S.

Risky TV sexual behavior may be modeled

Expert: Media pressures teens to have sex

Prostitute jailed for soliciting with HIV

Men 'on the down low' fear disclosure

Cost-effective HIV monitoring system found

Meek immune response helps AIDS survival

Long term sought for HIV-secretive man

Study evaluates HIV genetic screening

Florida doctors guilty of Medicare fraud

CDC: Blacks, gays most at risk for HIV

Calif. man to get his 'HIV' vanity plate

STDs increase HIV risk if exposed

Iran arrests chill anti-AIDS exchanges

Study: Why U.S. teens don't use condoms

Swaziland king's lavish lifestyle slammed

Brain cells may attack immune system

Increase in bone fractures linked to HIV

NYC HIV spreading at triple the U.S. rate